Combined vaccination with her-2 peptide followed by therapy with vegf peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1048-1060

  Foy, Kevin C ^a   Miller, Megan J ^a   Moldovan, Nicanor ^a   Carson, William E ^b   Kaumaya, Pravin T P ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Antibodies; Peptides; Peptides epitopes; Peptidomimetic

Indexed keywords

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GLYCYLISOLEUCYLHISTIDYLGLUTAMINYLGLYCYLGLUTAMINYLHISTIDYLPROLYLLYSYLISOLEUCYLARGINYLMETHIONYLISOLEUCINE VACCINE; ISOLEUCYLMETHIONYLARGINYLISOLEUCYLLYSYLPROLYLHISTIDYLGLUTAMINYLGLYCYLGLUTAMINYLHISTIDYLISOLEUCYLGLYCINE VACCINE; KI 67 ANTIGEN; LEUCYLVALYLTHREONYLTYROSYLASPARAGINYLTHREONYLTHREONYLASPARAGINYLTHREONYLPHENYLALANYLGLUTAMYLSERYLMETHIONYLPROLYLASPARAGINYLPROLYLGLUTAMYLGLYCYLARGINYLTYROSYLTHREONYLPHENYLALANYLGLYCYLALANYLSERYLCYSTEINYLVALINE VACCINE; PEPTIDE VACCINE; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; TUMOR XENOGRAFT; UPREGULATION; VACCINATION;

EID: 84886313817     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20708     Document Type: Article

References (40)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/10.1126/science. 3798106.
2. Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD, et al. The structural basis for the specificity of epidermal growth factor and heregulin binding. J Biol Chem 1995; 270:9585-9; PMID:7721889; http://dx.doi.org/10.1074/ jbc.270.16.9585.
3. Leu M, Bellmunt E, Schwander M, Fariñas I, Brenner HR, Müller U. Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development. Development 2003; 130:2291-301; PMID:12702645; http://dx.doi.org/10.1242/ dev.00447.
4. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84:7159-63; PMID:2890160; http://dx.doi. org/10.1073/pnas.84.20.7159.
5. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006; 24:5658-63; PMID:17102066; http://dx.doi.org/10.1200/ JCO.2006.07.0250.
6. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92:1253-60; PMID:15785739; http://dx.doi. org/10.1038/sj.bjc.6602499.
7. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24:2376-85; PMID:16710036; http://dx.doi.org/10.1200/ JCO.2005.03.4827.
8. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15:65-71; PMID:16328035.
9. Cirisano FD, Karlan BY. The role of the HER-2/ neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996; 3:99-105; PMID:8796816; http:// dx.doi.org/10.1016/1071-5576(96)00001-9.
10. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004; PMID:11359907; http://dx.doi. org/10.1128/MCB.21.12.3995-4004.2001.
11. Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, et al. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep 2003; 10:1271-4; PMID:12883692.
12. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003; 102:964-71; PMID:12689940; http://dx.doi.org/10.1182/blood- 2002-12-3738.
13. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59:1592-8; PMID:10197634.
14. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5:89-97; PMID:7515293; http://dx.doi.org/10.1016/0955-2235(94)90019-1.
15. Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64:38-46; PMID:16377414; http://dx.doi.org/10.1016/j. ijrobp.2005.02.008.
16. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http:// dx.doi.org/10.1016/S1535-6108(04)00083-2.
17. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69:46-56; PMID:16301835; http://dx.doi.org/10.1159/000088483.
18. Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472-82; PMID:17579068.
19. Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem.
20. Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PTP, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180-8; PMID:12165548.
21. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http:// dx.doi.org/10.1016/S1535-6108(02)00097-1.
22. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
23. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995; 3:21-6; PMID:7621075; http://dx.doi. org/10.1016/1074-7613(95)90155-8.
24. Wary KK, Thakker GD, Humtsoe JO, Yang J. Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2003; 2:25; PMID:12904264; http://dx.doi.org/10.1186/1476-4598-2-25.
25. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9:43-9; PMID:15178815; http://dx.doi.org/10.1634/ theoncologist.9-suppl_1-43.
26. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-8; PMID:12177445; http://dx.doi. org/10.1073/pnas.172398299.
27. Carpenito C, Davis PD, Dougherty ST, Dougherty GJ. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2002; 54:1473-8; PMID:12459373; http:// dx.doi.org/10.1016/S0360-3016(02)03921-4.
28. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101:1316-23; PMID:12406876; http://dx.doi.org/10.1182/blood- 2002-07-2184.
29. Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8:1008-13; PMID:11948107.
30. Stern DF, Kamps MP. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J 1988; 7:995-1001; PMID:3261240.
31. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990; 61:1339-47; PMID:1973074; http://dx.doi.org/10.1016/0092-8674(90)90697-D.
32. Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011; 286:13612-25; PMID:21321115; http:// dx.doi.org/10.1074/jbc.M110.216812.
33. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going. Br J Cancer 2004; 90:1-7; PMID:14710197; http://dx.doi. org/10.1038/sj.bjc.6601401.
34. Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 2004; 279:24141-51; PMID:15060075; http://dx.doi.org/10.1074/jbc. M313210200.
35. Söll R, Beck-Sickinger AG. On the synthesis of orexin A: a novel one-step procedure to obtain peptides with two intramolecular disulphide bonds. J Pept Sci 2000; 6:387-97; PMID:10969868; http://dx.doi. org/10.1002/1099-1387(200008)6:8<387::AIDPSC267387> 3.0.CO;2-M.
36. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/ Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133-42; PMID:11046045.
37. Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170:4242-53; PMID:12682258.
38. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 2003; 171:2637-43; PMID:12928417.
39. Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 2001; 276:22892-900; PMID:11303022; http://dx.doi.org/10.1074/jbc. M011647200.
40. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007; 26:328-33; PMID:17581420; http:// dx.doi.org/10.1097/01.pgp.0000235065.31301.3e.